Last reviewed · How we verify
SHR4640 ; Febuxostat
At a glance
| Generic name | SHR4640 ; Febuxostat |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia (PHASE2)
- Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia (PHASE2)
- A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia (PHASE2)
- The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia (PHASE1)
- The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |